Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis
Cancers · 24.06.2023 · 15 (13) · 3325
DOI: 10.3390/cancers15133325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 24.06.2023. Verfasst von Munaser Alamoodi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Hope Foundation.
Abstract (Originalsprache)
Recent advances in systemic treatment for breast cancer have been underpinned by recognising and exploiting subtype-specific vulnerabilities to achieve higher rates of pathologic complete response (pCR) after neo-adjuvant systemic therapy (NAST). This down-staging of disease has permitted safe surgical de-escalation in patients who respond well. Triple-negative (TNBC) or HER2-positive breast cancer is most likely to achieve complete radiological response (rCR) and pCR after NAST. Hence, for selected patients, particularly those who are clinically node-negative (cN0) at diagnosis, the probability of disease in the sentinel node after NAST could be low enough to justify omitting axillary surgery. The aim of this pooled analysis was to determine the rate of sentinel node positivity (ypN+) in patients with TNBC or HER2-positive breast cancer who were initially cN0, achieving rCR and/or pCR in the breast after NAST. MedLine was searched using appropriate search terms. Five studies (N = 3834) were included in the pooled analysis, yielding a pooled ypN+ rate of 2.16% (95% CI: 1.70–2.63). This is significantly lower than the acceptable false negative rate of sentinel lymph node biopsy (SLNB) and supports consideration of omission of SLNB in this subset of patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- The London Breast Institute, Princess Grace Hospital, London W1U 5NY, UK.
- Department of Surgery, Khyber Teaching Hospital, Peshawar 25120, Pakistan.
- College of Medicine and Health, University of Exeter Medical School, Exeter EX1 2LU, UK.
- Department of General Surgery, University College London Hospital, Euston Road, London NW1 2BU, UK.
- Department of General Surgery, Royal Free Hospital, London NW3 2QG, UK.
ORCID-Profile: Umar Wazir, Jajini Varghese
Förderung
- Breast Cancer Hope Foundation
Zitieren
APA
Alamoodi, M., Wazir, U., Mokbel, K., Patani, N., Varghese, J., & Mokbel, K. (2023). Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis. Cancers, 15(13), 3325. https://doi.org/10.3390/cancers15133325
Vancouver
Alamoodi M, Wazir U, Mokbel K, Patani N, Varghese J, Mokbel K. Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis. Cancers. 2023;15(13):3325. doi:10.3390/cancers15133325
BibTeX
@article{Alamoodi2023,
author = {Alamoodi, Munaser and Wazir, Umar and Mokbel, Kinan and Patani, Neill and Varghese, Jajini and Mokbel, Kefah},
title = {Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis},
journal = {Cancers},
year = {2023},
volume = {15},
number = {13},
pages = {3325},
doi = {10.3390/cancers15133325}
}
EUVIMED